Sciact
  • EN
  • RU

Effects of Dendrimer-microRNA Nanoformulations against Glioblastoma Stem Cells Научная публикация

Журнал Pharmaceutics
ISSN: 1999-4923
Вых. Данные Год: 2023, Том: 15, Номер: 3, Страницы: 968-968 Страниц : 1 DOI: 10.3390/pharmaceutics15030968
Ключевые слова 3D tumor models; dendrimers; glioblastoma; microRNA; nanomedicine; nucleic acid therapeutics; surface markers; tumor stem cells
Авторы Knauer Nadezhda 1,2 , Meschaninova Mariya I. 3 , Muhammad Sajjad 2 , Hänggi Daniel 2 , Majoral Jean‐Pierre 4 , Kahlert Ulf D. 5 , Kozlov V.А. 1 , Apartsin Evgeny 6
Организации
1 Clinic for Neurosurgery, Medical Faculty, Heinrich-Heine University Medical Center Düsseldorf, 40225 Düsseldorf, Germany
2 Research Institute of Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia
3 Institute of Chemical Biology and Fundamental Medicine SB RAS, 630090 Novosibirsk, Russia
4 Laboratoire de Chimie de Coordination, CNRS, 205 Route de Narbonne, CEDEX 04, 31077 Toulouse, France
5 Molecular and Experimental Surgery, Clinic for General-, Visceral-, Vascular-, and Transplant-Surgery, Medical Faculty, University Hospital Magdeburg, 39120 Magdeburg, Germany
6 Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, 33600 Pessac, France

Реферат: Glioblastoma is a rapidly progressing tumor quite resistant to conventional treatment. These features are currently assigned to a self-sustaining population of glioblastoma stem cells. Anti-tumor stem cell therapy calls for a new means of treatment. In particular, microRNA-based treatment is a solution, which in turn requires specific carriers for intracellular delivery of functional oligonucleotides. Herein, we report a preclinical in vitro validation of antitumor activity of nanoformulations containing antitumor microRNA miR-34a and microRNA-21 synthetic inhibitor and polycationic phosphorus and carbosilane dendrimers. The testing was carried out in a panel of glioblastoma and glioma cell lines, glioblastoma stem-like cells and induced pluripotent stem cells. We have shown dendrimer-microRNA nanoformulations to induce cell death in a controllable manner, with cytotoxic effects being more pronounced in tumor cells than in non-tumor stem cells. Furthermore, nanoformulations affected the expression of proteins responsible for interactions between the tumor and its immune microenvironment: surface markers (PD-L1, TIM3, CD47) and IL-10. Our findings evidence the potential of dendrimer-based therapeutic constructions for the anti-tumor stem cell therapy worth further investigation.
Библиографическая ссылка: Knauer N. , Meschaninova M.I. , Muhammad S. , Hänggi D. , Majoral J. , Kahlert U.D. , Kozlov V.А. , Apartsin E.
Effects of Dendrimer-microRNA Nanoformulations against Glioblastoma Stem Cells
Pharmaceutics. 2023. V.15. N3. P.968-968. DOI: 10.3390/pharmaceutics15030968 WOS Scopus OpenAlex
Даты:
Опубликована в печати: 17 мар. 2023 г.
Идентификаторы БД:
Web of science: WOS:000957822200001
Scopus: 2-s2.0-85151733480
OpenAlex: W4327730487
Цитирование в БД:
БД Цитирований
OpenAlex 8
Scopus 5
Web of science 5
Альметрики: